STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

GENE GENETIC TECHNOLOGIES LIMITED StockScouter® Report

5

StockScouter® Score

GENETIC TECHNOLOGIES LIMITED, a micro cap company in the healthcare sector, is expected to perform in line with the market over the next six months with slightly higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The multi-period measure of relative price change and consistency is well above average. Positive
  • The enterprise value-to-sales ratio is approximately in line with that of comparably-sized companies in the StockScouter universe. Neutral

 

Concerns

  • Short-term relative price momentum exhibits meaningful weakness. Negative
  • Moving average analysis for GENE suggests downward price movement over the medium term. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be in favor, stocks will be , and healthcare stocks will be in favor.

Expected Risk/Return

Progress: 80% done.
Progress: 60% done.
Low
High

Core Model Grades

N/A
C
C
A

Previous Ratings

6
3
3